Skip to content

Bristol-Myers Squibb Company Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Bristol-Myers Squibb Company · E.BMY.NYSE · United States
Use symbol E.BMY.NYSE in our API & Excel add-in to retrieve this data ↓
61.39
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -50%
Trend 25%
Bubble Risk LOW
Realised Volatility (20D) 36.56%

Bristol-Myers Squibb Company Forecast

Bristol-Myers Squibb Company short-term momentum is negative (up over 1 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 36.6% a year, a typical one-standard-deviation range is 58.23–64.55 over a week, 54.91–67.87 over a month and 38.95–83.83 over a year. (Signals as of 1 Nov 2026.)

Bristol-Myers Squibb Company Price Chart

MacroFinance.ai

Bristol-Myers Squibb Company Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Bristol-Myers Squibb Company
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Bristol-Myers Squibb Company
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Bristol-Myers Squibb Company
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Bristol-Myers Squibb Company
P/E
13.64x
Mid-range vs own history
QoQ −7.8%
YoY −12.6%
now 13.635613.04 low20.92 high
ⓘP/E As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Bristol-Myers Squibb Company
P/S
2.52x
Mid-range vs own history
QoQ −9.7%
YoY +28.4%
now 2.5192.09 low2.79 high
ⓘP/S As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Bristol-Myers Squibb Company
P/B
5.39x
Mid-range vs own history
QoQ −12.4%
YoY +6.0%
now 5.38515.16 low6.89 high
ⓘP/B As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Bristol-Myers Squibb Company
EV/EBITDA
10.45x
Mid-range vs own history
QoQ +3.8%
YoY +20.9%
now 10.44649.05 low10.86 high
ⓘEV/EBITDA As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Bristol-Myers Squibb Company
EV/Sales
3.16x
Mid-range vs own history
QoQ −8.1%
YoY +18.0%
now 3.16312.81 low3.44 high
ⓘEV/Sales As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Bristol-Myers Squibb Company
FCF Yield
7.4%
Weak vs own history
QoQ −11.6%
YoY −54.6%
now 7.36797.13 low15.26 high
ⓘFCF Yield As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Bristol-Myers Squibb Company
Earnings Yield
7.3%
Strong vs own history
QoQ +8.4%
YoY +14.5%
now 7.33384.78 low7.67 high
ⓘEarnings Yield As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Bristol-Myers Squibb Company
Dividend Yield
4.1%
Mid-range vs own history
QoQ +9.4%
YoY −23.4%
now 4.06163.71 low4.99 high
ⓘDividend Yield As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Bristol-Myers Squibb Company
Market Cap
$126.0B
Mid-range vs own history
QoQ −8.2%
YoY +33.7%
now 126033.67100,268 low137,236 high
ⓘMarket Cap As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Bristol-Myers Squibb Company
Net Debt
$32.2B
Mid-range vs own history
QoQ +0.5%
YoY −6.7%
now 3222932,053 low36,466 high
ⓘNet Debt As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Bristol-Myers Squibb Company
Net Debt / EBITDA
2.13x
Mid-range vs own history
QoQ +11.6%
YoY −8.2%
now 2.12731.91 low2.4 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Bristol-Myers Squibb Company
Current Ratio
1.59x
Strong vs own history
QoQ +3.6%
YoY +25.3%
now 1.58731.26 low1.59 high
ⓘCurrent Ratio As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Bristol-Myers Squibb Company
Quick Ratio
1.44x
Strong vs own history
QoQ +4.2%
YoY +23.5%
now 1.44311.14 low1.44 high
ⓘQuick Ratio As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Bristol-Myers Squibb Company
Interest Coverage
7.86x
Mid-range vs own history
QoQ −0.4%
YoY +53.8%
now 7.85545.11 low7.88 high
ⓘInterest Coverage As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Bristol-Myers Squibb Company
Debt / Equity
1.91x
Mid-range vs own history
QoQ −0.9%
YoY −30.4%
now 1.91461.91 low2.75 high
ⓘDebt / Equity As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Bristol-Myers Squibb Company
Piotroski F-Score
7
Mid-range vs own history
QoQ 0.0%
YoY +16.7%
now 76 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Bristol-Myers Squibb Company
Altman Z-Score
2.69
Strong vs own history
QoQ −3.9%
YoY +41.5%
now 2.68621.94 low2.8 high
ⓘAltman Z-Score As of 22 Nov 2026.See Bristol-Myers Squibb Company returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Bristol-Myers Squibb Company, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Bristol-Myers Squibb Company fundamentals: income statement, balance sheet & cash flow

Bristol-Myers Squibb Company reported revenue of $48.20bn and net income of $7.05bn in FY2025, the year ended 31 December 2025 — revenue down 0.2% and net income up 178.8% on the prior year. Free cash flow was $12.85bn. These figures are as reported in the filings, not restated: 39 fiscal years and 159 quarters of history, back to December 1987. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$48.20bn
-0.2%
Net income
$7.05bn
+178.8%
Gross margin
71.08%
Free cash flow
$12.85bn
-7.9%
Net debt
$36.93bn
Shares short (30 Oct 2026)
46.85m
4.24 days to cover
Bristol-Myers Squibb Company income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue48.2048.3045.0146.1646.39
Cost of revenue13.9413.9710.6910.149.94
Gross profit34.2634.3334.3136.0236.45
Research & development9.9511.169.309.5110.20
Selling, general & admin.—17.2916.8217.4117.71
Operating income13.725.898.209.108.54
EBITDA15.233.1719.3719.2220.12
Interest expense1.891.951.171.231.33
Pre-tax income9.33-8.388.447.718.10
Income tax2.270.550.401.371.08
Net income7.05-8.958.036.336.99

Download Bristol-Myers Squibb Company fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BMY.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 39 fiscal years and 159 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Bristol-Myers Squibb Company

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Bristol-Myers Squibb Company Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Bristol-Myers Squibb Company; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Bristol-Myers Squibb Company’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Bristol-Myers Squibb Company behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Bristol-Myers Squibb Company (United States)

Bristol-Myers Squibb Company is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Bloomsbury Publishing Plc

Frequently asked questions

What is Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Bristol-Myers Squibb Company price?
The latest close is 61.39 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Bristol-Myers Squibb Company in an uptrend?
As of 1 Nov 2026, short-term momentum is negative (1 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is positive (5 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Bristol-Myers Squibb Company?
20-day realised volatility is 36.6% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 10.6% over a month and 5.1% over a week.
What factors affect Bristol-Myers Squibb Company?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Bristol-Myers Squibb Company, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Bristol-Myers Squibb Company?
58 backtested tactical asset allocation strategies trade Bristol-Myers Squibb Company through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Bristol-Myers Squibb Company returns analysed?
The Statistical Distribution of Returns section shows the distribution of Bristol-Myers Squibb Company daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Bristol-Myers Squibb Company historical data?
In the Free historical data section of this page: the last 10 years of Bristol-Myers Squibb Company daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Bristol-Myers Squibb Company historical data (last 10 years)

Browse or instantly download the last 10 years of Bristol-Myers Squibb Company daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BMY.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2058.8
2026-11-1958.34
2026-11-1859.56
2026-11-1761.35
2026-11-1662.93
2026-11-1363.43
2026-11-1262.32
2026-11-1162.91
2026-11-1062.8
2026-11-0962.14
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.